# Drug-Drug Interaction Prediction Agent

**ID:** `biomedical.drug_discovery.ddi_prediction`
**Version:** 1.0.0
**Status:** Production
**Category:** Drug Discovery / Safety Pharmacology

---

## Overview

The **Drug-Drug Interaction (DDI) Prediction Agent** predicts pharmacokinetic and pharmacodynamic interactions between drugs using deep learning, knowledge graphs, and transformer-based NLP models. DDIs are a major cause of adverse drug events, particularly in elderly patients on multiple medications (polypharmacy).

This agent integrates structural features, metabolic pathway information, and literature-derived knowledge to provide comprehensive interaction predictions with mechanistic explanations.

---

## Key Capabilities

### 1. Interaction Type Prediction

| Type | Mechanism | Example |
|------|-----------|---------|
| **PK - Absorption** | GI pH, P-gp inhibition | Omeprazole + Clopidogrel |
| **PK - Distribution** | Protein binding displacement | Warfarin + NSAIDs |
| **PK - Metabolism** | CYP inhibition/induction | Ketoconazole + Midazolam |
| **PK - Excretion** | Renal transporter interaction | Probenecid + Penicillin |
| **PD - Synergistic** | Same pathway, additive effect | ACE inhibitor + ARB |
| **PD - Antagonistic** | Opposing effects | Beta-blocker + Beta-agonist |

### 2. CYP Interaction Prediction

| CYP Enzyme | Common Substrates | Key Inhibitors | Inducers |
|------------|-------------------|----------------|----------|
| **CYP3A4** | Midazolam, Simvastatin | Ketoconazole, Ritonavir | Rifampin, Carbamazepine |
| **CYP2D6** | Codeine, Tamoxifen | Fluoxetine, Paroxetine | None significant |
| **CYP2C9** | Warfarin, Phenytoin | Fluconazole, Amiodarone | Rifampin |
| **CYP2C19** | Omeprazole, Clopidogrel | Fluoxetine, Fluvoxamine | Rifampin |
| **CYP1A2** | Theophylline, Caffeine | Fluvoxamine, Ciprofloxacin | Smoking, Omeprazole |

### 3. Severity Classification

- **Contraindicated:** Avoid combination
- **Major:** High clinical significance, may require intervention
- **Moderate:** Clinical monitoring recommended
- **Minor:** Limited clinical significance

### 4. Multi-Drug Analysis

- Pairwise interaction screening
- Network-based interaction analysis
- Polypharmacy risk assessment
- Alternative drug suggestions

---

## Usage

### Example Prompt

```text
Predict drug-drug interactions for a patient taking:
1. Warfarin (anticoagulant)
2. Omeprazole (PPI)
3. Simvastatin (statin)
4. Amiodarone (antiarrhythmic)

Identify all pairwise interactions, severity, mechanisms, and clinical recommendations.
```

### Expected Output

```
## Drug-Drug Interaction Analysis

### Patient Medication List
| Drug | Class | Primary CYP Metabolism |
|------|-------|------------------------|
| Warfarin | Anticoagulant | CYP2C9, CYP3A4 |
| Omeprazole | PPI | CYP2C19, CYP3A4 |
| Simvastatin | Statin | CYP3A4 |
| Amiodarone | Antiarrhythmic | CYP3A4 (inhibitor) |

### Identified Interactions

#### 1. Warfarin + Amiodarone ⚠️ MAJOR
| Aspect | Details |
|--------|---------|
| **Severity** | Major |
| **Mechanism** | Amiodarone inhibits CYP2C9, reducing warfarin metabolism |
| **Effect** | ↑ INR, ↑ bleeding risk (30-50% dose reduction needed) |
| **Onset** | Delayed (1-4 weeks due to long amiodarone half-life) |
| **Evidence** | Well-documented, multiple case reports |

**Recommendation:** Reduce warfarin dose by 30-50%. Monitor INR weekly for 4-6 weeks.

#### 2. Simvastatin + Amiodarone ⚠️ MAJOR
| Aspect | Details |
|--------|---------|
| **Severity** | Major |
| **Mechanism** | Amiodarone inhibits CYP3A4, increasing simvastatin levels |
| **Effect** | ↑ Risk of myopathy and rhabdomyolysis |
| **Max Dose** | Simvastatin should not exceed 20 mg daily |
| **Evidence** | FDA warning issued |

**Recommendation:** Limit simvastatin to 20 mg/day OR switch to pravastatin/rosuvastatin.

#### 3. Warfarin + Omeprazole 🟡 MODERATE
| Aspect | Details |
|--------|---------|
| **Severity** | Moderate |
| **Mechanism** | Omeprazole may inhibit CYP2C19, affecting S-warfarin metabolism |
| **Effect** | Possible modest ↑ INR |
| **Clinical Significance** | Variable, often minimal |
| **Evidence** | Conflicting data |

**Recommendation:** Monitor INR; usually no dose adjustment needed.

#### 4. Simvastatin + Omeprazole 🟢 MINOR
| Aspect | Details |
|--------|---------|
| **Severity** | Minor |
| **Mechanism** | Weak interaction via CYP3A4 |
| **Effect** | Minimal clinical impact |

**Recommendation:** No action required.

### Interaction Network
```
         Amiodarone
          /      \
   (CYP2C9)    (CYP3A4)
        /          \
    Warfarin ---- Simvastatin
        \          /
      (CYP2C19)  (CYP3A4)
          \      /
         Omeprazole
```

### Summary Risk Assessment

| Risk Level | Count | Interactions |
|------------|-------|--------------|
| Major | 2 | Warfarin-Amiodarone, Simvastatin-Amiodarone |
| Moderate | 1 | Warfarin-Omeprazole |
| Minor | 1 | Simvastatin-Omeprazole |

### Clinical Recommendations
1. **Warfarin:** Reduce dose 30-50%, frequent INR monitoring
2. **Simvastatin:** Limit to 20 mg OR switch to pravastatin
3. **Consider alternative:** Atorvastatin (lower CYP3A4 dependence) or pravastatin (no CYP metabolism)
```

### LLM Agent Integration

```python
@tool
def predict_ddi(
    drug1: str,
    drug2: str,
    include_mechanism: bool = True,
    include_recommendations: bool = True
) -> str:
    """
    Predicts drug-drug interaction between two drugs.

    Args:
        drug1: Drug name, DrugBank ID, or SMILES
        drug2: Drug name, DrugBank ID, or SMILES
        include_mechanism: Include mechanistic explanation
        include_recommendations: Include clinical recommendations

    Returns:
        DDI prediction with severity and mechanism
    """
    pass


@tool
def analyze_polypharmacy(
    drug_list: list[str],
    patient_age: int = None,
    renal_function: str = "normal"
) -> str:
    """
    Analyzes drug-drug interactions in a medication list.

    Args:
        drug_list: List of drug names or identifiers
        patient_age: Patient age for geriatric considerations
        renal_function: normal, mild, moderate, or severe impairment

    Returns:
        Comprehensive interaction analysis
    """
    pass
```

---

## Prerequisites

### Required Databases

| Resource | Purpose | Access |
|----------|---------|--------|
| **DrugBank** | Drug information | API (licensed) |
| **DDInter** | DDI database | Public |
| **TWOSIDES** | Literature-mined DDIs | Public |
| **ChEMBL** | Bioactivity data | Public API |
| **FDA Drug Labels** | Official DDI warnings | DailyMed |

### Dependencies

```
rdkit>=2023.03
torch>=2.0
transformers>=4.30  # BioBERT/DrugBERT
pandas>=1.5
networkx>=3.0
requests>=2.28
```

---

## Methodology

### Model Architecture

```
Drug Pair Input
    ↓
Feature Extraction
    ├── Structural: Morgan FP, GNN embeddings
    ├── Pharmacological: Target profiles, ATC codes
    └── Textual: BioBERT embeddings of drug descriptions
    ↓
Knowledge Graph Integration
    ├── Drug-Target-Drug paths
    ├── Drug-Enzyme-Drug paths
    └── Drug-Transporter-Drug paths
    ↓
Interaction Prediction
    ├── Binary: Interaction yes/no
    ├── Type: PK/PD classification
    └── Severity: Multi-class prediction
    ↓
Mechanism Explanation
    ├── CYP pathway analysis
    └── Literature evidence retrieval
    ↓
Clinical Recommendations
```

### DDI Prediction Model

```python
import torch
import torch.nn as nn
from torch_geometric.nn import GCNConv

class DDIPredictionModel(nn.Module):
    def __init__(self, drug_dim=2048, hidden_dim=512):
        super().__init__()

        # Drug encoders
        self.drug_encoder = nn.Sequential(
            nn.Linear(drug_dim, hidden_dim),
            nn.ReLU(),
            nn.Dropout(0.3),
            nn.Linear(hidden_dim, hidden_dim)
        )

        # Knowledge graph encoder
        self.kg_conv1 = GCNConv(hidden_dim, hidden_dim)
        self.kg_conv2 = GCNConv(hidden_dim, hidden_dim)

        # Interaction predictor
        self.interaction_head = nn.Sequential(
            nn.Linear(hidden_dim * 2, hidden_dim),
            nn.ReLU(),
            nn.Linear(hidden_dim, 128),
            nn.ReLU(),
            nn.Linear(128, 1),
            nn.Sigmoid()
        )

        # Severity classifier
        self.severity_head = nn.Sequential(
            nn.Linear(hidden_dim * 2, 128),
            nn.ReLU(),
            nn.Linear(128, 4)  # Contraindicated, Major, Moderate, Minor
        )

    def forward(self, drug1_features, drug2_features, kg_data=None):
        # Encode drugs
        h1 = self.drug_encoder(drug1_features)
        h2 = self.drug_encoder(drug2_features)

        # Knowledge graph enhancement (if available)
        if kg_data is not None:
            h1 = self.kg_conv1(h1, kg_data.edge_index)
            h2 = self.kg_conv1(h2, kg_data.edge_index)

        # Combine drug representations
        combined = torch.cat([h1, h2, h1 * h2, torch.abs(h1 - h2)], dim=-1)

        # Predict
        interaction_prob = self.interaction_head(combined[:, :1024])
        severity_logits = self.severity_head(combined[:, :1024])

        return interaction_prob, severity_logits
```

### CYP Interaction Analysis

```python
def analyze_cyp_interactions(drug1: str, drug2: str) -> dict:
    """
    Analyze CYP-mediated drug-drug interactions.
    """
    cyp_profiles = {
        drug1: get_cyp_profile(drug1),  # {substrate: [], inhibitor: [], inducer: []}
        drug2: get_cyp_profile(drug2)
    }

    interactions = []

    # Check if drug1 affects drug2 metabolism
    for cyp in cyp_profiles[drug1]['inhibitor']:
        if cyp in cyp_profiles[drug2]['substrate']:
            interactions.append({
                'perpetrator': drug1,
                'victim': drug2,
                'mechanism': f'{drug1} inhibits {cyp}, reducing {drug2} metabolism',
                'effect': f'Increased {drug2} exposure'
            })

    for cyp in cyp_profiles[drug1]['inducer']:
        if cyp in cyp_profiles[drug2]['substrate']:
            interactions.append({
                'perpetrator': drug1,
                'victim': drug2,
                'mechanism': f'{drug1} induces {cyp}, increasing {drug2} metabolism',
                'effect': f'Decreased {drug2} exposure'
            })

    return interactions
```

---

## Related Skills

- **Multi-Endpoint Toxicity Agent:** Comprehensive safety assessment
- **Clinical Trial Eligibility Agent:** Concomitant medication screening
- **Pharmacovigilance Agent:** Post-market DDI surveillance

---

## References

- **Ryu et al. (2018):** "Deep learning improves prediction of drug–drug and drug–food interactions." *PNAS*
- **Sun et al. (2025):** "HDN-DDI: High-accuracy drug-drug interaction prediction using multimodal features." *Briefings in Bioinformatics*
- [DrugBank DDI Module](https://go.drugbank.com/drug-interaction-checker)
- [Drugs.com Interaction Checker](https://www.drugs.com/drug_interactions.html)

---

## Author

**MD BABU MIA**
*Artificial Intelligence Group*
*Icahn School of Medicine at Mount Sinai*
md.babu.mia@mssm.edu
